Search
forLearn
5 / 801 resultslearn Bimatoprost
a synthetic prostamide used to treat eyelashes also shows promise for stimulating hair growth on scalp
learn Fo-ti
learn fusidic acid
learn FC550
Research
5 / 1000+ results![Comparative Oncology: Evaluation of 2-Deoxy-2-[18F]Fluoro-D-Glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for the Staging of Dogs with Malignant Tumors](/images/research/d55cf8d9-d8ee-4735-9b38-42a266b4059d/small/24322.jpg)
research Comparative Oncology: Evaluation of 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for the Staging of Dogs with Malignant Tumors
FDG PET/CT scans can change cancer treatment plans for dogs.
research Shedding light on the FDA’s 510(k) approvals process: low-level laser therapy devices used in the treatment of androgenetic alopecia
LLLT devices for hair loss need more research to define proper guidelines.
research FDA Reports of Alopecia as an Adverse Event to Isotretinoin
Isotretinoin may cause hair loss, especially in women and young adults.
research Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
Finasteride may be linked to Peyronie’s disease, but more research is needed.
research 18F-FDG PET Uptake in the Scalp After Platelet-Rich Plasma Therapy
Platelet-rich plasma therapy can increase FDG uptake in the scalp.
Community Join
5 / 1000+ resultscommunity FDA Policy Shift Explained: What It Actually Means for PP405, VDPHL-01, Breezula and Hair Loss Drug Timelines
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
community FDA approves Cassiopea's WINLEVI (CB-03-01, 1% formulation) for Acne
The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.
community US FDA will now default to only one clinical trial for drug applications, will this accelerate the release of PP405 and other drugs in clinical trials?
The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.
community New warning by FDA on topical finasteride
The FDA warned that topical finasteride can cause serious side effects like sexual dysfunction and brain fog, similar to oral finasteride. Compounded topical formulations pose additional risks due to lack of regulation.
community Alright so FDA better approve PP405 as fast as they approved covid vaccine
PP405 is a potential hair loss treatment showing promising early results, with hopes for market release by 2028, but skepticism remains due to inconclusive data and past disappointments with similar products. Current treatments like Minoxidil and Finasteride have side effects, leading some to anticipate PP405 as a safer alternative, though its effectiveness compared to placebo is debated.